PATRIC is one of six NIAID-funded Bioinformatics Resource Centers (BRCs) for Infectious Diseases and focuses on bacterial species. The BRCs compile large datasets in a standardized way, allowing scientists to perform analyses more efficiently. This can include assessing the function of specific genes, identifying markers for diagnosing a particular bacterial infection, or discovering new bacterial resistance mechanisms.
A clinical trial comparing three chemotherapy regimens in combination with antiretroviral treatment for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early.
The collaboration made possible the rapid and robust sharing of Zika materials such as Zika isolates and serum samples.
A new video from NIAID explores a possible new way to fight bacteria as they become increasingly resistant to antibiotics.
Each year, NIAID-funded scientists visit the beaches of Delaware Bay to test shorebirds for avian flu viruses. A video from NIAID Now profiles their work.
In a new study in Science Translational Medicine, NIAID-funded researchers probe the tuberculosis bacterium’s cell membrane construction processes—and find a weakness that future TB drugs could exploit to halt the bacteria’s growth.
NIAID is conducting and supporting research, including two clinical trials, on the potentially deadly disease Valley fever, or coccidioidomycosis. People can get Valley fever by inhaling a soil-residing fungus endemic to parts of the southwestern United States.
In 2016, an estimated 216 million people developed malaria. In a new video from NIAID, Dr. Lee Hall, chief of the Parasitology and International Programs Branch in NIAID’s Division of Microbiology and Infectious Diseases, discusses the urgent need for malaria research, and how NIAID is supporting and conducting investigation into new diagnostics, drugs, vaccines and more.
Dr. Erica Ollmann Saphire, speaker at the 2017 Joseph J. Kinyoun Memorial Lecture, has spearheaded a global effort to find antibodies that work against small-genomed viruses like Ebola and Lassa.
Bacterial infections that resist antibiotics are a major problem in the United States. In 2015, the U.S. government launched the National Action Plan for Combating Antibiotic-Resistant Bacteria. Guided by the plan, NIAID and other NIH components work with government, academic, and industry partners on a wide range of projects aimed at understanding and controlling antibiotic resistance. To mark this year’s Antibiotic Awareness Week, November 13-19, we highlight a few of these efforts.
NIAID-funded scientists have found that a new Zika vaccine candidate can protect pregnant mice and their fetuses, as well as male mice and monkeys, with just one dose.
Findings from a pair of NIAID-funded studies in zebrafish shed light on how nerve damage is initiated in leprosy and suggest a potential target for the development of strategies to prevent tuberculosis and other mycobacterial diseases.
It’s easy for people to overlook the importance of fast, reliable diagnostic tests in scientific research. Most often, ill patients focus on what treatment is available for them to recover. But without a timely and accurate diagnosis, physicians won’t know the most optimal treatment to provide.
In recent years, multidrug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis (TB) has become increasingly common—and difficult to treat. A new study funded by NIAID reveals that by unravelling the TB bacteria’s DNA and testing it for certain mutations, researchers were able to estimate to what extent the bacteria are resistant to fluoroquinolones, a class of powerful antibiotics typically used to treat TB.
Each May, NIAID-funded researchers descend on the beaches of Delaware Bay in New Jersey to screen migratory shorebirds for the flu. Through this work, they are learning more about how influenza viruses spread and evolve.
Read the report and recommendations on a possible Zika virus human challenge study.
View the meeting summary from the joint WHO and NIAID/NIH conference on Zika Virus vaccine development.
First-Line Treatment of TB for Drug-Sensitive TB. Tuberculosis, which results from an infection with Mycobacterium tuberculosis, can be cured with a combination of first-line drugs taken daily for several months. Shown here are the four drugs in the standard regimen of first-line drugs. Also shown are the dates these four drugs were discovered—all more than 40 years ago.